chrisvoncsefalvay/vaers-outcomes huggingface dataset:
on-going fatigue; Eye issues started on day 3:  light sensitivity; eye soreness; itchy eye; burning feeling in eye; Have some chills; headache; This is a spontaneous report from a contactable consumer or other non hcp reported about herself (patient).    A 80-year-old female patient received bnt162b2 (BNT162B2; Solution for injection; Lot Number: EL9262), via an unspecified route of administration, administered in left arm as dose number unknown, single on 10Feb2021 (at the age of 80-year-old) for covid-19 immunisation. Patient was not pregnant at time of vaccination. The patient's medical history included atrial tachycardia and no known allergies. Concomitant medications included flecainide, losartan, diltiazem and ropinirole all taken for an unspecified indication, start and stop date were not reported. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine and received other medication within 2 weeks of vaccination: flecainide, losartan, diltiazem and ropinirole. On 12Feb2021, the patient experienced fatigue starting next day, eye issues started on day 3: Light sensitivity, soreness, itchy, burning feeling and had some chills, headache, on-going fatigue. No therapeutic measures were taken as a result of events. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for nasal swab COVID-19 POC was negative on 17Feb2021. Lab tests and procedures which included SARS-COV-2 test: negative on 17Feb2021. At the time of this report, outcome of the events was not recovered.  Follow-up attempts are completed. No further information is expected.
Tested COVID-19 positive; Loss of Taste; Little bit of headache; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Tested COVID-19 positive), AGEUSIA (Loss of Taste) and HEADACHE (Little bit of headache) in a 47-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 11-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 23-Mar-2021, the patient experienced AGEUSIA (Loss of Taste) and HEADACHE (Little bit of headache). On 24-Mar-2021, the patient experienced COVID-19 (Tested COVID-19 positive). At the time of the report, COVID-19 (Tested COVID-19 positive) and HEADACHE (Little bit of headache) outcome was unknown and AGEUSIA (Loss of Taste) was resolving.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 24-Mar-2021, SARS-CoV-2 test: positive (Positive) positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by the reporter. Treatment information was not provided.
An apparent case of shingles, bad itching all over the body, small bumps, and skin mottling. Like last time I had shingles, 10 years ago, but worse. Was advised to take Benadryl. Doctor appt. tomorrow morning.
The event that occurred was that the patient had received Trumemba brand Men B for his 1st dose of Men B- and it was never explained that Bexero Men B is not interchangeable for the 2nd dose, and the patient should have gotten Trumemba Men B
We have some Moderna Covid-019 vaccine that was given after the expiration date.; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (We have some Moderna Covid-019 vaccine that was given after the expiration date.) in a 72-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 091D21A) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (We have some Moderna Covid-019 vaccine that was given after the expiration date.). At the time of the report, EXPIRED PRODUCT ADMINISTERED (We have some Moderna Covid-019 vaccine that was given after the expiration date.) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter. No treatment information was provided.
PFIZER COVID VACCINE #3 GIVEN 10/13/21, LOT #FE3590; pt admitted to hospital with worsening dyspnea x 2 months; had a permanent pacemaker placed 1 month prior to admission; dyspnea has been worse since placement; found to be positive for COVID; administered "standard treatment for COVID" per medical report; ABX given; pt condition worsened; DNR; pt passed away in the hospital
Patient was seated in waiting room after receiving vaccine she is over 18 but her mother was with her and said she has a history of fainting after vaccines.  She fainted while seated for a few seconds and  then came to then she said she felt sick to her stomach we brought her a trash can patient vomited she said she then felt much better we watched her in waiting area for next half hour gave cold water patient said she felt fine after 30 minutes of observation
My grandson was force vaccinated against my daughter's consent. My daughter has a severe learning disability and has authorized me to advocate on her behalf, so I'm helping her submit this report.  We've observed seizures, muscle freezing, problems with constipation and diarrhea, slapping his ears really hard, and high pitched screaming starting spring of 2016. He was taken from her at birth and her now ex-husband, a convicted pedophile only allowed her to hold him twice. They were rescued from their predator, but father was able to manipulate 50/50 custody. Pt was vaccinated without her consent.
On 25Dec2021, the patient experienced contracted with covid; On 25Dec2021, the patient experienced contracted with covid; This is a solicited report received from contactable reporter(s) (Consumer or other non HCP) for a sponsored program. The reporter is the patient. Other Case identifier(s): 22K-163-4238018-00 (Agency).  A 59 year-old male patient received bnt162b2 (BNT162B2), intramuscular, administration date 23Dec2021 (Batch/Lot number: unknown) at the age of 59 years as dose 3 (booster), single, intramuscular (Batch/Lot number: unknown) as dose 2, single and intramuscular (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation; adalimumab (HUMIRA), subcutaneous (Lot number: 1155267) at citrate free for rheumatoid arthritis. The patient's relevant medical history was not reported. There were no concomitant medications. The following information was reported: DRUG INEFFECTIVE (medically significant) with onset Dec2021, outcome "unknown", COVID-19 (medically significant) with onset 25Dec2021, outcome "recovered" and all described as "On 25Dec2021, the patient experienced contracted with covid". The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (Dec2021) positive. The action taken for adalimumab was unknown. The reporter's assessment of the causal relationship of the event with the suspect product was not provided at the time of this report. Since no determination has been received, the case is managed based on the company causality. The lot number for bnt162b2 was not provided and will be requested during follow up.; Sender's Comments: Based on the current available information and the plausible drug-event temporal association, a possible contributory role of the suspect product BNT162B2 to the development of events drug ineffective and covid19 cannot be totally excluded.
first MPSV4/was given MCV4 on 7/28/2021; This case was reported by a other health professional via call center representative and described the occurrence of interchange of vaccine products in a 15-year-old female patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVA517A, expiry date 30th April 2022) for prophylaxis.   Previously administered products included MPSV4 (1st dose received on 5th October 2016 (received at the age of 11 years)).   On 28th July 2021, the patient received the 2nd dose of Menveo. On 28th July 2021, unknown after receiving Menveo, the patient experienced interchange of vaccine products. On an unknown date, the outcome of the interchange of vaccine products was unknown.  Additional details were reported as follows: On 5th October 2016, the patient received 1st dose of MPSV4 vaccine at the age of 11 years. As per CDC, minimum age for vaccination for this type of Menongococcal vaccine was 16 years. On 28th July 2021, the patient received 2nd dose as a Menveo (MCV4), which led to interchange of vaccine products. The reporter consented to follow up. This case has been linked to US2020259323, reported by the same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020259323:Same reporter
pt came to clinic p/vax w/ c/o stiffness & pain @ the back of neck, states even hear cracking sound when turning head to sides;denies pain or swelling of inj site;pt wondering if vax can exacerbate arthritis;
Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) in a 41-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 07-Jan-2021 at 2:00 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 07-Jan-2021 at 2:00 PM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The age of patient was provided as 41.91 years.  Concomitant and Treatment medications were not reported.  It was reported that, the storage condition at the time of the excursion was cooler storage during high-pace COVID-19 vaccination clinic.  The vials were only punctured right before administration and all doses were drawn from the vial due to high-pace clinic.  Temperature recordings were taken using a brand traceable temperature monitor at every hour. It was reported that, the patient was administered with vaccine that experienced more than 1 temperature excursion during 33 weeks on 2021. The health care professional explained that each time a vial was put into a cooler, there was a period of 1 hour or 1 hour and a half approximately, when the temperature data logger registered 34 or 35 degree Fahrenheit.   This case was linked to MOD-2022-566976 (Patient Link).
It seemed to have caused shingles and was given Valtrex and it resolved the issue still have tingles from the shingles
Local swelling, erythema, induration within 6l hours of administration. Prolonged deep muscle pain, tingling in hands, malaise, myalgias, chills, flushing.
Pain in site of injection from the moment of injection. Pain/soreness in arm decreased with time, but was still able to feel a small amount of soreness up until 2-3 weeks. Vaccine was taken at 6:15pm, later that night after I had gone to bed I woke up with chills. In the morning, I tried to eat breakfast but immediately felt nauseous and began feeling really hot. I stood up to change into cooler clothes but the heat/nausea got worse and I began to lose my vision. I was about to faint, but felt immediately better once I lay down and elevated my legs. I had a temperature of 99F. Fever lasted a few hours (I took ibuprofen). I got a headache at around 11AM, but slept it off with a nap. By the end of the afternoon I was feeling much better, with the arm pain/soreness as my only remaining symptom.
Pt received Moderna COVID vaccines around March - April 2021. Pt admitted to hospital in August with thrombocytopenia. Unknown case. Treating as ITP. Physician concern with possibility of vaccine induced thrombocytopenia however timeframe is much longer than previously reported cases. Platelets not recorded prior to admission. During admission platelets dropped to 22.
Information has been received from a physician concerning a 16 year old female who on 12-OCT-2007 was vaccinated with a dose of Gardasil. After the patient had received the vaccination, the patient had fainted to the point where the physician thought she was convulsing. Unspecified medical attention was sought. Subsequently the patient recovered on the same day. No product quality complaint was involved. Additional information has been requested.
Pt. reports was running approx. 6pm 08/20/2013 suddenly "felt sick" and weak after 1 mile and had to go home and lie down. Temp was 99. On 08/21/2013 developed nausea most of day. 08/21 PM noted rash only on back, was resolved with Benadryl cream. Temp still 99.  Woke 08/22/2013 am with arm of injection "painful to raise", "tingling into hand". Denied pain, redness, or swelling at injection site left arm. Was instructed to discuss with primary MD.
Pt presented at the ED 01/22/2022 for evaluation of low heart rate. Patient states he  had COVID-like symptoms for 2 weeks; fatigue. He states yesterday his symptoms got worse and he started to feel  SOB.  Tested + 01/21/2022. Pt has a pacemaker and the home monitoring system called and alerted him that his heart rate was in the 30s and he should go to the ER. Pt was admitted. Pt died 01/29/2021 of acute respiratory failure with hypoxia, COVID pneumonia, acute CHF exacerbation and lactic acidosis.
Brain feels like it is about to explode; developed a fever of 102 for 10 days since the first dose and won't go away; This spontaneous case was reported by a consumer and describes the occurrence of HEAD DISCOMFORT (Brain feels like it is about to explode) and PYREXIA (developed a fever of 102 for 10 days since the first dose and won't go away) in a 30-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 040C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced HEAD DISCOMFORT (Brain feels like it is about to explode) and PYREXIA (developed a fever of 102 for 10 days since the first dose and won't go away). At the time of the report, HEAD DISCOMFORT (Brain feels like it is about to explode) and PYREXIA (developed a fever of 102 for 10 days since the first dose and won't go away) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 03-Aug-2021, Body temperature: 102 (High) Fever of 102 for 10 days.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications information was reported. No treatment medications were provided. This spontaneous case was reported by a consumer and describes the occurrence of HEAD DISCOMFORT (Brain feels like it is about to explode) and PYREXIA (developed a fever of 102 for 10 days since the first dose and won't go away) in a 30-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 040C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced HEAD DISCOMFORT (Brain feels like it is about to explode) and PYREXIA (developed a fever of 102 for 10 days since the first dose and won't go away). At the time of the report, HEAD DISCOMFORT (Brain feels like it is about to explode) and PYREXIA (developed a fever of 102 for 10 days since the first dose and won't go away) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 03-Aug-2021, Body temperature: 102 (High) Fever of 102 for 10 days.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications information was reported. No treatment medications were provided.
Information has been received from a physician concerning a 26 year old female medical student with no medical history and no allergies who on 01-Jul-1998 and 14-Feb-2001 was vaccinated with a first and second dose of varicella virus vaccine live. Concomitant therapy included "nodette". It was reported that the patient received 2 doses of the vaccine within a 3 year interval. During the week of 19-May-2003 the patient had a titer drawn which was reported as negative. Medical attention was sought and no treatment was required. No product quality complaint was involved. On 17-Jul-2003 information was received from the physician who reported that there was no adverse vaccine experience, he noted that he had simply called to get advice from the company about using varicella virus vaccine live. No further information is expected.
This is in follow-up to report (s) previously submitted on 4/13/2007. Information has been received from a nurse concerning her daughter an 18 year old female who in February 2007, was vaccinated with Gardasil vaccine (yeast) (dose and date not provided). Subsequently the patient experienced heart palpitations that disappeared after 2 weeks. The patient did seek unspecified medical attention and had an electrocardiogram performed, results not available. Subsequently, the patient recovered from heart palpitations. Information has been received from a nurse concerning her 18 year old daughter with an allergy to ALEVE who in March 2007 (also reported as February 2007), was vaccinated with a first dose of GARDASIL. Concomitant therapy included hormonal contraceptives (unspecified). Within 24 hours of vaccination, the patient experienced heart palpitations that dissappeared after 2 weeks. It was also reported in follow-up that the patient developed shortness of breath and dizziness. The patient did seek unspecified medical attention and had an electrocardiogram performed, results not available. Subsequently, the patient recovered from heart palpitations, shortness of breath and dizziness. In follow-up it was reported that on 08-MAY-2007 or 09--MAY-2007, the patient was vaccinated with a second dose of GARDASIL. Three to four hours post-vaccination (also reported as within 8 hours), at dinner time, the patient developed sweating, severe heart palpitations, dizziness and shortness of breath (also reported as "similar symptoms" as with the first dose). The patient's mother also stated that the patient's arm was very sore. The patient went to the local emergency room. An EKG was performed and the results were normal, however, the patient was given an EKG halter moniter to wear for 24 hours. An EEG was also performed (results unknown). The patient was seen by a cardiologist. The heart palpitations contnued for days and after about 1 week, the patient recovered from the heart palpitations. At the time of this report, the results of the EKG halter monitor test were not available. The patient's gynecologist thought that this was an isolated incident. The patient was not hospitalized. The patient was subsequently diagnosed with premature ventricular contractions (PVCs) without true tachycardia. The patient had no history of PVCs but her mother was currently on medications for PVCs. It was stated that the patient will not received the third dose of GARDASIL. At the time of this report, the outcome of the sweating, PVCs dizziness and shortness of breath was unknown and the patient had not recovered from the very sore arm. No product quality complaint was involved. Additional information is not expected.
Injection at 1:00pm. Intense itching torso, head, neck, arms at 3:00pm. Took TYLENOL & BENADRYL by mouth 3:15pm.
Weakness and tightness in throat initially followed by a 103 degree fever around 3 AM. On 10/19/2016, had hot and cold spells and diminished appetite. In the evening, another 103 degree fever. On 10/20/2016, fever continued and even weaker to the point I could not hold anything and barely walking. On the 21st, symptoms diminished but still felt extremely weak. All that was taken was Motrin and weakness still persists after a week now.
sore arm both times that all; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 32 year-old female patient received bnt162b2 (BNT162B2), administered in arm left, administration date 16Sep2021 (Lot number: 301308A) at the age of 32 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "Asymptomatic COVID-19", start date: May2021 (unspecified if ongoing). Concomitant medication(s) included: DEPO-PROVERA. Vaccination history included: Bnt162b2 (Dose 1, single, Batch/Lot number: FC3183, Anatomical Site of injection: Right arm), administration date: 26Aug2021, when the patient was 32 years old, for Covid-19 immunization. The following information was reported: PAIN IN EXTREMITY (non-serious) with onset 2021, outcome "unknown", described as "sore arm both times that all". Relevant laboratory tests and procedures are available in the appropriate section. No follow-up attempts are possible. No further information is expected.
the pregnant patient was administered one dose of GARDASIL 9; No adverse effects; This spontaneous report was received from a physician referring to a female patient of unknown age. Information about medical history, concurrent conditions and concomitant therapies was not provided.    On 11-SEP-2019, this pregnant patient was vaccinated with one dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) injection (lot # and expiration date were not reported) via intramuscular route for prophylaxis (maternal exposure during pregnancy). Information about the last menstrual period (LMP) and estimated date of delivery (EDD) was not known. The pregnancy outcome was outcome pending. No adverse effects were reported.